Unfiltered thoughts on drugs, disease, evidence, and the strange beauty of a discipline that sits at the intersection of chemistry, physiology, and clinical medicine.
Every pharmacologist I have ever admired has had one trait in common: an almost unreasonable curiosity about why a molecule does what it does in a body. Not just the textbook answer — the receptor, the second messenger, the downstream effect — but the full, untidy, contradictory truth of how a drug behaves in a living system shaped by age, genetics, disease, fear, and the half-eaten meal from two hours ago.
I am starting this diary because pharmacology deserves more than tables of drug names and mechanisms. It deserves to be thought about out loud. Every trial result is a story. Every adverse effect is a hypothesis. Every new molecule approved by the FDA is the end of a sentence that began, sometimes decades ago, with someone staring at a receptor crystal structure and thinking: what if we blocked this?
Today I read a network meta-analysis in JAMA — 716 trials, over 150,000 patients — comparing how well people tolerate blood pressure medications. Not whether the drugs lower BP. Whether patients stay on them. The finding is simple, and in retrospect obvious: ARBs combined with calcium channel blockers have fewer dropouts due to side effects than almost anything else, including placebo. Placebo. Think about that for a moment. A drug that controls blood pressure, with fewer side effects than taking nothing.
This is why mechanisms matter. ARBs block angiotensin II at the AT₁ receptor — they don't touch ACE, they don't let bradykinin accumulate, and so there is no cough. The cough that makes one in ten patients abandon ACE inhibitors isn't a curiosity. It is a kinins problem. Bradykinin, unopposed by ACE, stimulates pulmonary afferents. Remove that pathway — as ARBs do — and you remove the cough. The tolerability advantage isn't magic. It's mechanism.
This is what I want these pages to be about. The mechanism behind the outcome. The story inside the statistic. The pharmacology beneath the prescribing decision.